Research and Markets: IMS Pharmaceutical Pricing & Reimbursement Concise Guide 2011: South Korea Provide Industry Players

DUBLIN--(BUSINESS WIRE)-- Research and Markets(http://www.researchandmarkets.com/research/54206d/ims_pharmaceutical) has announced the addition of the "IMS Pharmaceutical Pricing & Reimbursement Concise Guide: South Korea" report to their offering.

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Key Topics Covered:

  • HEALTHCARE SYSTEM
  • PRICING
  • Prescription Drugs
  • Generic Drugs
  • Hospital Drugs
  • OTC Drugs
  • REIMBURSEMENT
  • Admission to Reimbursement
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Changes in Reimbursement Status
  • Changes in Reimbursement Prices
  • PHARMACOECONOMICS
  • Pharmacoeconomic Requirements
  • Price Build Up
  • Wholesalers Retail Pharmacies
  • Dispensing Doctors
  • Sales Tax
  • COST CONTAINMENT
  • Industry Paybacks
  • Promotional Costs
  • Patient Co-payments
  • Prescribing Controls
  • Generics
  • Rx-to-OTC Switches
  • Parallel Trade
  • FUTURE DEVELOPMENTS
  • Outlook
  • NAMES & ADDRESSES

For more information visit http://www.researchandmarkets.com/research/54206d/ims_pharmaceutical

Source: IMS Health



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Asia Pacific  South Korea

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.